MediPharm | Heritage and technicalisation
Overview
Founded in 1995, MediPharm is a manufacturing company whose know how is built on aseptic production of dry injections, liquid injections and infusion solutions for contract partners. The company provides contract manufacturing services to both local and global pharmaceutical and medical clients and combines regulated production with applied R&D in lyophilisation and finished dosage forms.
Company capabilities and manufacturing scope
- Core competence: aseptic manufacture of dry injectables, liquid injectables and infusion solutions for contract partners.
- Market reach: serves clients at an international level.
- Manufacturing operations: preparation of WFI and purified steam; preparation and inspection of primary packaging; precise dispensing and weighing of active substances and excipients; formulation and buffer preparation; sterilising filtration; aseptic filling and stopper placement; terminal sterilisation for appropriate product families; lyophilisation for selected sterile dosage forms; visual and automated optical inspection; final inspection, rework controls and batch release; labelling and secondary packaging.
- Quality systems: GMP‑compliant quality management including batch release, QC microbiology and analytical chemistry testing, sterility testing, stability studies, cleaning and depyrogenation validation, environmental monitoring, validated cleaning procedures, personnel training and gowning, change control and CAPA.
- Utilities and facilities: validated WFI system and purified steam; classified HVAC and cleanroom suites supporting aseptic zones; validated process equipment and automated control systems; documented calibration and maintenance programmes.
- Process distinctions: infusion solutions and bulk liquid parenterals typically undergo validated terminal sterilisation; lyophilised products and heat‑sensitive injectables are processed via aseptic/lyophilisation routes with appropriate sterility assurance measures.
Corporate history and milestones
Current R&D and certification plans
- Regulatory scope and certification: The company is extending its authorised scope to include formal R&D activities and is preparing a regulatory dossier to support certification by the Ministry of Health and alignment with EU GMP expectations. Documentation will include a quality manual, validation master plan, process descriptions, GMP‑compliant SOPs and supporting validation reports.
- Lyophilisation R&D unit: Operates a dedicated, classified cleanroom development line for lyophilisation and aseptic pilot processing. Activities cover process development, cycle optimisation, pilot scale tech transfer, and generation of batch records and transfer protocols for scale up.
- Analytical and QC capabilities: On site QC supports method development and release testing, including sterility testing, bacterial endotoxin testing, microbial environmental monitoring, and chemical analysis by HPLC (assay and impurities). Analytical methods are validated according to ICH and GMP principles.
- Stability and validation: Stability programmes executed under ICH conditions (accelerated and long term) with documented protocols and reportable stability indicating parameters. Validation scope includes process validation strategies, equipment qualification (IQ/OQ/PQ), cycle validation for lyophilisation and sterilization, and cleaning/depyrogenation validation.
- Quality systems and data integrity: GMP compliant quality management in place covering change control, CAPA, deviation handling, batch release, supplier qualification, and document control. Electronic data systems and LIMS are validated and governed by data integrity controls and access management.
- Facilities, utilities and assurance: Classified HVAC and cleanroom suites support separation of R&D and production activities. Utilities include a validated WFI system, purified steam and controlled compressed gases. Environmental monitoring programmes and personnel gowning/training maintain sterility assurance levels; media fill programmes are used to demonstrate aseptic process control.
- Organisation and competencies: Dedicated R&D team comprising formulation scientists, process engineers, analytical chemists and QC microbiologists, supported by QA/Responsible Person oversight and documented training records.
- Deliverables and impact: Outputs include validated manufacturing documentation (SOPs, validation reports, batch records), tech transfer packages, stability reports and analytical method dossiers to support regulatory submissions, reduce reliance on contract orders and enable proprietary product development and academic collaborations.
Final summary
Founded in 1995, MediPharm is a GMP‑certified contract manufacturer serving Central Europe, EU markets and selected international clients. Core competencies comprise aseptic manufacture of dry injectables, liquid injectables and infusion solutions, supported by classified cleanrooms, validated utilities (WFI, purified steam) and automated process controls.
Historical partnerships
Early-stage collaborations with LACHEMA and LÉČIVA acted as catalysts for operational and regulatory development; these partners have since been integrated into larger pharmaceutical conglomerates. Subsequent contractual and strategic relationships include Vipharm, Zentiva and Teva, together with selective site acquisitions and facility upgrades.
Manufacturing and facility profile
Operations run in classified cleanroom suites with segregated pilot and production areas (Grade A/B/C/D controlled environments). Utilities and critical systems are subject to qualification and validation programmes; core utilities (WFI, purified steam) and critical equipment have completed IQ/OQ and PQ is progressing for new lines.
Technical capabilities
End to end aseptic production including precise dispensing, sterilising filtration, aseptic filling and stopper placement, lyophilisation, terminal sterilisation where appropriate, optical inspection, final inspection, rework controls and batch release. Process automation and environmental monitoring underpin sterility assurance, with routine media fill programmes to demonstrate aseptic control.
QA/QC and analytical capabilities
GMP quality systems covering change control, CAPA, deviations, supplier qualification and batch documentation. On site QC performs sterility testing (USP/Ph. Eur. methods), bacterial endotoxin testing (LAL), microbial environmental monitoring and chemical analysis by validated HPLC methods for assay and impurities. Validated LIMS and electronic records support data integrity, access control and audit trails.
Stability and validation
Stability programmes executed under ICH Q1A conditions (accelerated and long term) with predefined timepoints and acceptance criteria. Validation scope includes equipment qualification (IQ/OQ/PQ), process validation strategies, cycle validation for lyophilisation and sterilisation, and cleaning/depyrogenation validation.
R&D and tech transfer
Dedicated lyophilisation and finished dosage form development unit performs process development, cycle optimisation, analytical characterisation, method validation, pilot scale tech transfer and preparation of validated manufacturing documentation (SOPs, VMP, batch records) to support scale up and regulatory filings.
Governance and personnel
QA oversight by a designated Responsible Person/Qualified Person; dedicated teams of formulation scientists, process engineers, analytical chemists and QC microbiologists with documented training records.
Ongoing investments in quality systems, infrastructure and applied research position MediPharm to supply regulated markets reliably, support regulatory submissions, and reduce dependence on external contractors through proprietary development and academic collaborations.